The Prognostic Value of PET/CT for Tumor Progression in Patients With Metastatic Hormone-sensitive Prostate Cancer

NCT06915714 | Completed

• 1 other identifier: IIT-2025-117
• Study Type: observational
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

Investigators retrospectively collected data from consecutive patients treated at the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, from October 2020 to March 2024. The inclusion criteria were as follows: (1) patients with diagnosis of metastatic hormone-sensitive prostate cancer, confirmed by PSA levels, radiographic tests and pathological information; (2) patients who underwent FDG and PSMA PET/CT prior to the initiation of medical treatment. The exclusion criteria were as follows: (1) patients who received novel hormone therapy or a prostate biopsy prior to PET/CT; (2) patients with other malignancies; (3) patients received hormone therapy without NHT; (4) patients received chemotherapy or radiotherapy prior to or during novel hormone therapy; (5) absence of follow-up data at the hospital.

Conditions

Prostate Cancer Metastatic Disease; PET / CT

Outcome Measures

Primary Outcomes (1)

• Castration-Resistant Prostate Cancer free survival (CRPC-FS)

  From date of the initiation of novel hormone therapy until the date of first documented either PSA or radiography-confirmed progression or date of the last follow-up for any cause, whichever came first, assessed up to 100 months

Study Arms (4)

Group1

PCa40%MTV-P = High, PCa40%MTV-G = Low

Group2

PCa40%MTV-P = Low, PCa40%MTV-G = High

Group3

PCa40%MTV-P = Low, PCa40%MTV-G = Low

Group4

PCa40%MTV-P = High, PCa40%MTV-G = High

Eligibility Criteria

• Sex: male
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All the enrolled patients were Asian(we are a affiliated hospital of a university based in Mainland china ).

You may qualify if:

• patients with diagnosis of metastatic hormone-sensitive prostate cancer, confirmed by PSA levels, radiographic tests and pathological information
• patients who underwent FDG and PSMA PET/CT prior to the initiation of medical treatment

You may not qualify if:

• patients who received novel hormone therapy or a prostate biopsy prior to PET/CT
• patients with other malignancies
• patients received hormone therapy without novel hormone therapy
• patients received chemotherapy or radiotherapy prior to or during novel hormone therapy
• absence of follow-up data at our institution

Sponsors & Collaborators

• Sun Yat-sen University: lead

Study Sites (1)

First affiliated hospital, Sun Yat-sen univeristy

Guangzhou, Guangdong, 510080, China

Location

Study Officials

• Fangzheng Xiang

  First affiliated hospital, Sun Yat-sen univeristy

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor, Phd, Md

Study Record Dates

• First Submitted: March 22, 2025
• First Posted: April 8, 2025
• Study Start: June 2, 2024
• Primary Completion: February 20, 2025
• Study Completion: February 28, 2025
• Last Updated: April 8, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)